A study of 14,360 early-stage breast cancer survivors showed that 10% of patients who had tamoxifen treatment developed diabetes during a mean follow-up time of 5.2 years. The findings suggest that tamoxifen may worsen an underlying diabetes risk in susceptible women, researchers reported in the journal Cancer.

Related Summaries